The UK ME/CFS Biobank for biomedical research on Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS) and Multiple Sclerosis.
Lacerda, Eliana M, Bowman, Erinna W, Cliff, Jacqueline M et al. · Open journal of bioresources · 2017 · DOI
Quick Summary
The UK ME/CFS Biobank is a collection of blood samples and health information from 284 people with ME/CFS, 60 people with multiple sclerosis, and 135 healthy volunteers. Researchers created this resource to help scientists study what causes ME/CFS and find better ways to diagnose and treat it. The samples and detailed patient information can be used by researchers worldwide to search for biological markers of the disease.
Why It Matters
This biobank addresses a critical gap in ME/CFS research by providing standardized, high-quality biological samples linked to detailed clinical data, enabling systematic investigation of disease mechanisms that have remained poorly understood. For patients, this resource accelerates the search for diagnostic biomarkers and potential therapeutic targets that could lead to better disease recognition and treatment options. The inclusion of MS cases as a comparator also helps distinguish ME/CFS-specific biological signatures from features common to other neurological conditions.
Observed Findings
Successful recruitment and biobanking of 284 clinically-confirmed ME/CFS cases alongside 60 MS cases and 135 healthy controls
Collection of 29,863 blood aliquots in multiple formats (serum, plasma, PBMCs, RBC/granulocyte pellets, whole blood, and RNA)
Comprehensive documentation of approximately 700 clinical and socio-demographic variables per participant
Participant age range of 18-60 years with clinician-confirmed diagnoses
Inferred Conclusions
A large, well-characterized biobank with standardized sample processing and extensive phenotypic data is feasible and valuable for ME/CFS research
Multiple sample types and formats enable diverse downstream analyses including immunological, metabolomic, and genomic studies
Incorporating both ME/CFS and MS cases provides an opportunity to identify disease-specific versus shared neurological features
This resource has potential to accelerate biomarker discovery and pathophysiology research when made available to qualified researchers under appropriate ethical oversight
Remaining Questions
What specific biomarkers or disease mechanisms can be identified through analysis of these samples in subsequent research studies?
How do biological profiles differ between ME/CFS cases with varying severity or symptom presentations represented in the biobank?
What This Study Does Not Prove
This study does not prove what causes ME/CFS or identify specific disease mechanisms—it only provides the infrastructure and samples for such research to occur. The biobank design does not establish correlations between any biological markers and disease severity or outcomes; such findings would require analysis studies conducted by subsequent researchers. The cross-sectional nature of sample collection means this resource cannot establish causality or temporal relationships between biological changes and symptom development.